Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Placebo-controlled, Parallel Group, Double-blinded, Single-center Phase-I, Pilot Study to Assess Tolerability and Safety of Repeated Subcutaneous Administration of ABvac40 in Patients With Mild to Moderate Alzheimer's Disease.

Next Previous
Search
Trial Profile

A Randomized, Placebo-controlled, Parallel Group, Double-blinded, Single-center Phase-I, Pilot Study to Assess Tolerability and Safety of Repeated Subcutaneous Administration of ABvac40 in Patients With Mild to Moderate Alzheimer's Disease.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 06 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ABvac 40 (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; First in man
  • Sponsors Araclon Biotech

Most Recent Events

  • 25 Jan 2018 According to an Araclon Biotech media release, this trial was conducted in partnership with TFS International (TFS).
  • 01 Aug 2016 Results presented at the Alzheimer's Association International Conference (AAIC 2016), according to an Araclon Biotech media release.
  • 01 Aug 2016 Results published in an Araclon Biotech media release.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top